Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trials of frexalimab versus teriflunomide in adults with relapsing multiple sclerosis
MOH_2024-02-28_013285Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Frexalimab IV plus oral placebo with Teriflunomide oral plus IV placebo (2 arms). Primary endpoints: Annualized relapse rate and Disability worsening. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2024-02-28_013285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-28_013285.